Kazakhstan Pharmaceuticals and Healthcare Report Q2 2008 : Market Research Report

Kazakhstan Pharmaceuticals and Healthcare Report Q2 2008

Published by: Business Monitor International

Published: Apr. 22, 2008 - 56 Pages

Executive Summary: Kazakhstan Pharmaceuticals And Healthcare SWOT; Kazakhstan Political SWOT; Kazakhstan Economic SWOT; Kazakhstan - Business Environment Ranking; Table: CEE Pharmaceutical Business Environment Ratings; Limits Of Potential Returns; Risks To Realisation Of Returns; Kazakhstan - Market Summary; Regulatory Regime; Intellectual Property Environment; Counterfeit Drugs; Pricing and Reimbursement Regime; Table: Price Components And Add-ons For Imported And Locally Produced Generic Medicines (KZT); Recent Pricing And Reimbursement Developments; Table Top 10 Manufacturers By Value Of Hospital; Table Top 10 INNs By Value Of Hospital Purchases; Industry Developments; Epidemiology; Healthcare Sector; Healthcare Sector Financing; Table: Top 10 ATC Groups By Value Of Hospital Purchase; Table: Top 10 ATC Groups By Retail Pharmacy Sales; Domestic Pharmaceutical Industry; Wholesale And Retail; Recent Domestic Industry Developments; Foreign Pharmaceutical Industry; Table: Indo-Kazakh Trade Figures (US$mn); Recent Foreign Industry Developments; Table: Pharmaniaga Key Products; Medical Devices; Table Medical Devices Market In Kazakhstan (US$mn); Industry Forecast Sce28; Overall Market Forecast; Table: Kazakhstan - Drug Expenditure And Prescription Market Indicators; Key Growth Factors - Industry; Table: Kazakhstan Health Expenditure Forecast Indicators; Key Growth Factors - Macroeconomic; Table: Economic Activity; Patented Market Forecast; Table: Kazakhstan’s Patented Drug Market Indicators (US$’000 unless otherwise stated); Generics Market Forecast; Table: Kazakhstan’s Generics Market Forecast Indicators; OTC Market Forecast; Table: Kazakhstan OTC Market Forecast Indicators (US$’000 unless otherwise stated); Export/Import Market Forecasts; Table: Trade Figures (US$mn); Table Retail Sales Structure Of Imports By Pharmaceutical Subgroups, 2006; Table: Top 15 Distributors By Value Importing Pharmaceuticals Into Kazakhstan, 2006; Table: Top 15 Distributors By Volume Importing Pharmaceuticals Into Kazakhstan, 2006; Other Healthcare Data Forecasts; Table: Other Healthcare Data; Key Risks To BMI’s Forecast Scenario; Competitive Landscape; Table: Top 10 Manufacturers By Value Of Hospital Purchases; Table: Top 10 Manufacturers By Retail Pharmacy Sales; Table: Top 10 Trade Names By Value Of Hospital Purchae; Table: Top 10 INNs By Value Of Hospital Purchases; Table: Top 10 INNs by Retail Pharmacy Sales; Company Monitor; Foreign Companies; Nycomed; Ranbaxy; Indigenous Companies; Chimpharm; Romat FK; BMI Forecast Modelling; How We Generate Our Industry Forecasts; Pharmaceutical Industry; Sources; Business Environment Ranking Pharmaceutical Ratings: Revised Methodology; Ratings Overview; Table: Pharmaceutical Business Environment Indicators

Abstract

The key driver for the expansion of the pharmaceutical market in Kazakhstan is the underlying economic
development and higher sales of oil. As BMI expects the economy to grow by around 8% in 2008, the
benefits should be translated in an increase in both healthcare and pharmaceutical expenditure. As part of
its healthcare system modernisation programme, the government is planning to raise the amount of GDP
spent on healthcare to 4% in 2008. By 2012, BMI expects the market to be worth around US$1.14bn,
growing at an annual rate in excess of 12%.Work on 56 hospitals and 83 outpatient hospitals scheduled
for 2008 will support this development.

However, in the BMI‘s revised Business Environment Ranking matrix for Central and Eastern Europe
(CEE) for Q208, Kazakhstan is ranked 15th of the 16 regional markets surveyed. The country is placed
only above Serbia, down one place from the previous quarter, when it shared the 14th spot with Ukraine.
While enjoying a considerable level of political and economic stability, the country is marked down for
absolute market value and per capita consumption of medicines, as well as the lack of universal
reimbursement. More recently, the government revealed plans to introduce a fixed average price for
outpatient medicines, which would be reflected negatively in market value and pharmaceutical
companies’ revenues.

Nevertheless, the market will remain reliant on imports. Leading foreign players include French Sanofi-
Aventis (France), Hungary’s Gedeon Richter, Swiss Nycomed and Berlin Chemie-Menarini.
Chimpharm is the main domestic producer of pharmaceuticals, accounting for over half of total local
output. In recent years, Asian generic companies (including Indian and Malaysian producers) have made
more of an impact on the Kazakhstan’s pharmaceutical marketplace, although this has also led to a rise in
counterfeit products.

In terms of other medical industries in Kazakhstan, the production of medical devices is relatively
limited, accounting for under 10% of the market. Key barriers to market access for foreign producers
include costly registration, the need for a Certificate of Conformance, tax levied on some medical devices
and the lack of transparency in public-sector procurement. On the other hand, healthcare system
modernisation, work on telemedicine and mobile medicine in rural regions and the government’s desire to
increase the role of the private sector will provide promising commercial opportunities for imports, which
are mostly sourced from Germany, Russia, the US and Japan.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

advertise with us

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Kazakhstan Pharmaceuticals and Healthcare Report Q2 2008

Table of Contents

Abstract